Medical management of brain tumors and the sequelae of treatment

Neuro-Oncology

Volumn 17, Issue 4, 2015, Pages 488-504

  Schiff, David ^a   Lee, Eudocia Q ^b   Nayak, Lakshmi ^b   Norden, Andrew D ^b   Reardon, David A ^b   Wen, Patrick Y ^b  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bevacizumab; Brain tumor; Chemotherapy; Cognition; Complications; Corticosteroids; Fatigue; Mood; Seizure; Symptom management; Vasogenic edema; Venous thromboembolism

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ARMODAFINIL; BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; DALTEPARIN; DEXAMETHASONE; DONEPEZIL; ENOXAPARIN; ETIRACETAM; GABAPENTIN; HARKOSERIDE; HEPARIN; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; MEMANTINE; MODAFINIL; PHENYTOIN; PLACEBO; PREGABALIN; PROCARBAZINE; RECOMBINANT COLONY STIMULATING FACTOR; TEMOZOLOMIDE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; WARFARIN;

ACOUSTIC NEURINOMA; ADVANCED CANCER; AGGRESSION; AGITATION; AMNESIA; ANEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATAXIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN METASTASIS; BRAIN RADIATION; CANCER SURVIVOR; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; COGNITIVE DEFECT; COGNITIVE THERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CRANIOTOMY; CUSHING SYNDROME; DELIRIUM; DEPRESSION; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; EDEMA; ENDOCRINE DISEASE; EPENDYMOMA; ERYTHROCYTE TRANSFUSION; EUPHORIA; EVIDENCE BASED MEDICINE; FATIGUE; GLIOBLASTOMA; GLIOMA; HAIR LOSS; HALLUCINATION; HEMANGIOBLASTOMA; HIP FRACTURE; HOARSENESS; HUMAN; HYPERAMMONEMIA; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; INFERTILITY; INSOMNIA; IRRITABILITY; KINESIOTHERAPY; LIMB WEAKNESS; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MANIA; MENTAL INSTABILITY; META ANALYSIS (TOPIC); METABOLIC ACIDOSIS; MOOD DISORDER; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROFIBROMATOSIS TYPE 2; NEUROLOGIC DISEASE; NEUROSURGERY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PARESTHESIA; PARKINSONISM; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; PSYCHOEDUCATION; PSYCHOSIS; QUALITY OF LIFE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK BENEFIT ANALYSIS; SEDATION; SEIZURE; SIDE EFFECT; SKIN BRUISING; SPINE FRACTURE; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; VASOGENIC EDEMA; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; VERTIGO; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; ADVERSE DRUG REACTION; BRAIN NEOPLASMS; COMPLICATION; PALLIATIVE THERAPY; RISK FACTOR; SEIZURES;

ADRENAL CORTEX HORMONES; ANTICONVULSANTS; BRAIN NEOPLASMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATIGUE; HUMANS; PALLIATIVE CARE; RISK FACTORS; SEIZURES; VENOUS THROMBOEMBOLISM;

EID: 84929150101     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou304     Document Type: Article

References (210)

1. Thom M, Blumcke I, Aronica E. Long-term epilepsy-associated tumors. Brain Pathol. 2012;22(3):350-379.
2. Compton JJ, Laack NN, Eckel LJ, et al. Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. J Neurosurg. 2012;117(5):825-830.
3. Alexiou GA, Varela M, Sfakianos G, et al. Benign lesions accompanied by intractable epilepsy in children. J Child Neurol. 2009;24(6):697-700.
4. Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137(Pt 2):449-462.
5. You G, Sha ZY, Yan W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol. 2012;14(2):230-241.
6. Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010;67(3):336-342.
7. Englot DJ, Berger MS, Barbaro NM, et al. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011;115(2):240-244.
8. Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis. 2004;1:(Suppl 1):S27-S33.
9. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-430.
10. Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10(2):124-133.
11. Ruda R, Bello L, Duffau H, et al. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14:(Suppl 4): iv55-iv64.
12. Sherman JH, Moldovan K, Yeoh HK, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114(6):1617-1621.
13. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43(8):1599-1601.
14. Ruda R, Magliola U, Bertero L, et al. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol. 2013;15(12):1739-1749.
15. Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13(9):e375-e382.
16. Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology. 1996;46(4):985-991.
17. Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol. 2010;23(6):603-609.
18. Foy PM, Copeland GP, Shaw MD. The incidence of postoperative seizures. Acta Neurochir (Wien). 1981;55(3-4):253-264.
19. Kuijlen JM, Teernstra OP, Kessels AG, et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure. 1996;5(4):291-298.
20. Pulman J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev. 2013;2: CD007286.
21. Wu AS, Trinh VT, Suki D, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013;118(4):873-883.
22. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886.
23. Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):97-102.
24. Perry J, Zinman L, Chambers A, et al. The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review. Curr Oncol. 2006;13(6):222-229.
25. Mamon HJ, Wen PY, Burns AC, et al. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999;40(3):341-344.
26. Delattre JY, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology. 1988;38(2):194.
27. Hoang-Xuan K, Delattre JY, Poisson M. Stevens-Johnson syndrome in a patient receiving cranial irradiation and carbamazepine. Neurology. 1990;40(7):1144-1145.
28. Taylor LP, Posner JB. Phenobarbital rheumatism in patients with brain tumor. Ann Neurol. 1989;25(1):92-4.
29. Werk EE Jr., Choi Y, Sholiton L, et al. Interference in the effect of dexamethasone by diphenylhydantoin. N Engl J Med. 1969;281(1):32-34.
30. Chalk JB, Ridgeway K, Brophy T, et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatr. 1984;47(10):1087-1090.
31. Lawson LA, Blouin RA, Smith RB, et al. Phenytoin-dexamethasone interaction: a previously unreported observation. Surg Neurol. 1981;16(1):23-24.
32. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med. 1989;87(5):505-510.
33. Levin VA, Stearns J, Byrd A, et al. The effect of phenobarbital pretreatment on the antitumor activity of 1, 3-bis (2-chloroethyl) - 1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2, 6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther. 1979;208(1):1-6.
34. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9(8):2940-2949.
35. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006;8(1):67-78.
36. Saria MG, Corle C, Hu J, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013;118(6):1183-1187.
37. Camphausen K, Cerna D, Scott T, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. 2005;114(3):380-386.
38. Kerkhof M, Dielemans JC, Van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(7):961-967.
39. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77(12):1156-1164.
40. Tsai HC, Wei KC, Tsai CN, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg. 2012;26(3):347-354.
41. Weller M. Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? Neuro Oncol. 2013;15(7):809-810.
42. Osoba D. Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Support Care Cancer. 2000;8(2):84-88.
43. Walsh D, Doona M, Molnar M, et al. Symptom control in advanced cancer: important drugs and routes of administration. Semin Oncol. 2000;27(1):69-83.
44. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
45. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277.
46. Ryan R, Booth S, Price S. Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neurooncol. 2012;106(3):449-459.
47. Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16(9):1041-1048.
48. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44(4):675.
49. Marantidou A, Levy C, Duquesne A, et al. Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol. 2010;100(1):89-94.
50. Deutsch MB, Panageas KS, Lassman AB, et al. Steroidmanagement in newly diagnosed glioblastoma. J Neurooncol. 2013;113(1):111-116.
51. Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer. 2002;10(4):322-328.
52. Weissman DE, Janjan NA, Erickson B, et al. Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neurooncol. 1991;11(3):235-239.
53. Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012;48(8):1176-1184.
54. Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25(18):2601-2606.
55. Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol. 2010;12(2):164-172.
56. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103-114.
57. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. 1997;48(5):1234.
58. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41(8):1235-1239.
59. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619-632.
60. Pezner RD, Lipsett JA. Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis. West J Med. 1982;137(5):375-378.
61. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735-740.
62. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111(7):541-545.
63. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735-740.
64. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111(7):541-545.
65. Weiner HL, Rezai AR, Cooper PR. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids. Neurosurgery. 1993;33(1):40-43.
66. Fadul CE, Lemann W, Thaler HT, et al. Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurology. 1988;38(3):348.
67. Curtis JR, Xie F, Chen L, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum. 2011;63(2):346-351.
68. Da Silva AN, Schiff D. Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor. Surg Neurol. 2007;67(5):508-510.
69. De Angelis LM, Posner JB. Supportive Care and its Complications. 3rd ed. New York, NY: Oxford University Press; 2009.
70. Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313-332.
71. Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15(12):1329-1334.
72. Recht L, Mechtler LL, Wong ET, et al. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy. J Clin Oncol. 2013;31(9):1182-1187.
73. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012;14:(Suppl 4): iv73-iv80.
74. Sawaya R, Zuccarello M, Elkalliny M, et al. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol. 1992;14(2):119-125.
75. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8(9):1959-1965.
76. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997;33(10):1592-1596.
77. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3):467-473.
78. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost. 2010;8(2):221-227.
79. Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost. 2014;40(3):325-331.
80. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13(3):334.
81. Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1992;43:1111.
82. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. 1987;66(3):357-358.
83. Schiff D, De Angelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73:493.
84. Alvarado G, Noor R, Bassett R, et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012;22(4):310-315.
85. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006;24(8):1310-1318.
86. Cavaliere R, Schiff D. Fatal pulmonary embolism despite an inferior vena cava filter in glioblastoma multiforme. Neurocrit Care. 2005;3(3):249-250.
87. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.: Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409-415.
88. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
89. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998;339(2):80-85.
90. Thaler J, Ay C, Kaider A, et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2014; [Epub ahead of print].
91. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
92. Cohen MH, Johnson JR, Justice R, et al. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008;13(6):709-714.
93. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953.
94. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
95. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
96. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101(12):1986-1994.
97. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12(12):1300-1310.
98. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14(21):7068-7073.
99. Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13(10):1143-1150.
100. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.
101. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63-70.
102. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187-193.
103. Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology. 2009;73(20):1677-1680.
104. Omar AI. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report. J Med Case Rep. 2012;6(1):238.
105. Bhaskara A, Eng C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer. 2008;7(1):65-68.
106. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol. 2010;100(3):443-447.
107. Kountourakis P, Dokou A, Kardara E, et al. Bevacizumab therapy may contribute to irradiation deferral in patients with breast cancer and with central nervous system metastases: findings of a case series. Clin Breast Cancer. 2012;12(4):282-286.
108. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010;79(5):1487-1495.
109. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
110. Hurwitz HI, Douglas PS, Middleton JP, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013;18(3):273-280.
111. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687-1691.
112. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596-604.
113. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-1136.
114. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186-193.
115. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010;46(2):439-448.
116. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45(2):281-287.
117. Saavedra E, Hollebecque A, Soria JC, et al. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs. 2014;32:774-782.
118. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285.
119. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757-1764.
120. Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2011;106(1):121-125.
121. Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79:(1-2):27-38.
122. Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013;71(6):1561-1565.
123. Khasraw M, Holodny A, Goldlust SA, et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol. 2011;23(2):458-463.
124. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269-278.
125. Fraum TJ, Kreisl TN, Sul J, et al. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011;105(2):281-289.
126. Seidel C, Hentschel B, Simon M, et al. A comprehensive analysis of vascular complications in 3, 889 glioma patients from the German Glioma Network. J Neurol. 2013;260(3):847-855.
127. Porcello Marrone LC, Marrone BF, Gadonski G, et al. Posterior reversible encephalopathy syndrome. Clin Adv Hematol Oncol. 2012;10(9):614-615.
128. Tlemsani C, Mir O, Boudou-Rouquette P, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6(4):253-258.
129. Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg. 2012;71(4):434-440.
130. Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011;114(6):1609-1616.
131. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577-582.
132. Abu-Hejleh T, Mezhir JJ, Goodheart MJ, et al. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14(4):277-284.
133. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559-568.
134. Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(6):660-668.
135. Armstrong TS, Cao Y, Scheurer ME, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009;11(6):825-832.
136. Villano JL, Letarte N, Yu JM, et al. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol. 2011;69(1):107-113.
137. Momota H, Narita Y, Miyakita Y, et al. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol. 2013;15(10):1445-1450.
138. Gaviani P, Silvani A, Lamperti E, et al. Infections in neuro-oncology. Neurol Sci. 2011;32:(Suppl 2):S233-S236.
139. Subach BR, Witham TF, Kondziolka D, et al. Morbidity and survival after 1, 3-bis (2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery. 1999;45(1):17-22; discussion-3.
140. McGovern PC, Lautenbach E, Brennan PJ, et al. Risk factors for postcraniotomy surgical site infection after 1, 3-bis (2-chloroethyl) - 1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis. 2003;36(6):759-765.
141. Chiang HY, Kamath AS, Pottinger JM, et al. Risk factors and outcomes associated with surgical site infections after craniotomy or craniectomy. J Neurosurg. 2014;120(2):509-521.
142. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887-2893.
143. Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol. 1991;48(4):406-409.
144. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol. 1996;27:235.
145. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375-1382.
146. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22(4):610-616.
147. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol. 2013;85(3):373-382.
148. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol. 2003;63(3):263-270.
149. Ridola V, Barone G, Lazzareschi I, et al. Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. J Neurooncol. 2011;103(1):147-153.
150. Meije Y, Lizasoain M, Garcia-Reyne A, et al. Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis. 2010;50(12):e73-e76.
151. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012;30(24):2963-2968.
152. Munhoz RR, Pereira Picarelli AA, Troques Mitteldorf CA, et al. Aspergillosis in a patient receiving temozolomide for the treatment of glioblastoma. Case Rep Oncol. 2013;6(2):410-415.
153. Aregawi D, Lopez D, Wick M, et al. Disseminated strongyloidiasis complicating glioblastoma therapy: a case report. J Neurooncol. 2009;94(3):439-443.
154. Redelman-Sidi G, Grommes C, Papanicolaou G. Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma. J Neurooncol. 2011;102(2):335-339.
155. Choi JD, Powers CJ, Vredenburgh JJ, et al. Cryptococcal meningitis in patients with glioma: a report of two cases. J Neurooncol. 2008;89(1):51-53.
156. De Paiva TF Jr., De Barros e Silva MJ, Rinck JA Jr., et al. Tuberculosis in a patient on temozolomide: a case report. J Neurooncol. 2009;92(1):33-35.
157. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med. 2007;356(15):1591-1592.
158. Fujimoto Y, Hashimoto N, Kinoshita M, et al. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol. 2012;17(3):290-293.
159. Chheda MG, Drappatz J, Greenberger NJ, et al. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology. 2007;68(12):955-956.
160. Tsutsumi Y, Yamamoto Y, Shimono J, et al. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol. 2013;5(11):612-620.
161. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765-2772.
162. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834-4840.
163. Sathyapalan T, Dixit S. Radiotherapy-induced hypopituitarism: a review. Expert Rev Anticancer Ther. 2012;12(5):669-683.
164. Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):379-390.
165. Preusser M, Seywald S, Elandt K, et al. Pilot study on sex hormone levels and fertility in women with malignant gliomas. J Neurooncol. 2012;107(2):387-394.
166. Strowd RE, Blackwood R, Brown M, et al. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. J Oncol Pharm Pract. 2013;19(4):321-327.
167. Palmieri C, Brock C, Newlands ES. Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma. J Neurooncol. 2005;73(2):185.
168. Sitbon Sitruk L, Sanson M, Prades M, et al. Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide. Gynecol Obstet Fertil. 2010;38(11):660-662.
169. Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro Oncol. 2012;14(Suppl 4): iv65-iv72.
170. Lovely M, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum. 1999;26(5):921-925.
171. National Comprehensive Cancer Network. Cancer-Related Fatigue (Version 1.2013). 2013. http://www.nccn.org/professionals/physician-gls/pdf/fatigue.pdf (accessed November 21, 2013.
172. Neefjes EC, Van Der Vorst MJ, Blauwhoff-Buskermolen S, et al. Aiming for a better understanding and management of cancer-related fatigue. Oncologist. 2013;18(10):1135-1143.
173. Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013;14(10):e407-e416.
174. Rooney A, Grant R. Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database Syst Rev. 2013;5: CD006932.
175. Rooney AG, McNamara S, Mackinnon M, et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J Clin Oncol. 2011;29(32):4307-4312.
176. De Raaf PJ, Van Der Rijt CC. Can you help me feel less exhausted all the time? J Clin Oncol. 2013;31(25):3056-3060.
177. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11: CD006145.
178. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076-3082.
179. Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7: CD006704.
180. Boele FW, Douw L, De Groot M, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol. 2013;15(10):1420-1428.
181. Shaw EG, Case D, Bryant D, et al. Phase II double-blind placebo-controlled study of armodafinil for brain radiation induced fatigue. J Clin Oncol. 2013;31(No 15 suppl(May 20 Supplement)):9505.
182. Lee EQ, Muzikansky A, Kesari S, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. J Clin Oncol. 2014;32(5 s): suppl; abstr 2004.
183. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol. 2004;5(7):399-408.
184. Crossen JR, Garwood D, Glatstein E, et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12(3):627-642.
185. Greene-Schloesser D, Moore E, Robbins ME. Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res. 2013;19(9):2294-2300.
186. Schnegg CI, Greene-Schloesser D, Kooshki M, et al. The PPARdelta agonist GW0742 inhibits neuroinflammation, but does not restore neurogenesis or prevent early delayed hippocampaldependent cognitive impairment after whole-brain irradiation. Free Radic Biol Med. 2013;61 C: 1-9.
187. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1760-1765.
188. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatmentassociated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675-3686.
189. Kazda T, Jancalek R, Pospisil P, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol. 2014;9:139.
190. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5(7):22.
191. Seigers R, Fardell JE. Neurobiological basis of chemotherapyinduced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35(3):729-741.
192. Gong X, Schwartz PH, Linskey ME, et al. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011;76(13):1126-1134.
193. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-1437.
194. Shaw EG, Rosdhal R, D'Agostino RB Jr., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415-1420.
195. Rapp S, Case D, Peiffer A, et al. Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors. J Clin Oncol. 2013;31: suppl: abstr 2006.
196. Gehring K, Patwardhan SY, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2012;107(1):165-174.
197. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522-2527.
198. Ji JF, Ji SJ, Sun R, et al. Forced running exercise attenuates hippocampal neurogenesis impairment and the neurocognitive deficits induced by whole-brain irradiation via the BDNFmediated pathway. Biochem Biophys Res Commun. 2014;443(2):646-651.
199. Boarini DJ, Beck DW, Van Gilder JC. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery. 1985;16(3):290-292.
200. Moots PL, Maciunas RJ, Eisert DR, et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol. 1995;52(7):717-724.
201. Mahaley MS Jr., Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol. 1981;16(6):399-401.
202. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien). 1990;103(1-2):47-51.
203. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci. 2003;30(2):106-112.
204. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg. 1983;58(5):672-677.
205. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
206. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
207. Grossman SA, O'Neill A, Grunnet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003;21(8):1485.
208. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168-1174.
209. Butler JM Jr., Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496-1501.
210. Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol. 2009;27(22):3712-3722.